Ascendis Pharma A/S (ASND)
NASDAQ · Healthcare · Biotechnology
Profile
Ascendis Pharma A/S
- Exchange
- NASDAQ
- Ticker
- ASND
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- DK
Ascendis Pharma A/S is a biopharmaceutical enterprise dedicated to advancing therapeutic solutions for critical medical conditions that currently lack effective treatments. Its commercialized offering is SKYTROFA, a therapy prescribed for individuals suffering from growth hormone deficiency (GHD). The company boasts a robust development pipeline, featuring several TransCon-branded candidates. These include TransCon Growth Hormone (hGH), which is being progressed for pediatric GHD patients in Japan and for adults with GHD. Also under development are TransCon parathyroid hormone for adults with hypoparathyroidism, and TransCon CNP, aimed at treating pediatric achondroplasia. Further expanding its innovative portfolio, Ascendis is also developing a TransCon toll-like receptor (TLR) 7/8 agonist for intratumoral administration, alongside TransCon IL-2 ß/g, designed for systemic delivery. Founded in 2006, this enterprise maintains its corporate headquarters in Hellerup, Denmark.
Key facts
Ascendis Pharma A/S: key facts
- Ascendis Pharma A/S (NASDAQ: ASND) is a Biotechnology company in the Healthcare sector.
- In fiscal 2025, Ascendis Pharma A/S reported revenue of 691.7M EUR and net income of -219.0M EUR.
- Revenue grew 207.1% a year over the last 4 fiscal years.
- Free cash flow was positive in 1 of the last 5 fiscal years.
- Net income was positive in 0 of the last 5 fiscal years.
- Over the last twelve months, revenue was 1.2B EUR and net income was 890.4M EUR.
MonkScore
Ascendis Pharma A/S's MonkScore
MonkScore
MonkScore range: 90–100
as of November 2026
Sector rank: 4 of 640 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth90–100
- Profitability90–100
- Quality50–59
- Market Conviction80–89
- Safety70–79
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–9 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Ascendis Pharma A/S's annual figures and the last twelve months, in EUR. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | 1.2B EUR | 691.7M EUR | 363.6M EUR | 266.7M EUR | 51.2M EUR | 7.8M EUR |
| Gross profit | 1.1B EUR | 588.5M EUR | 319.4M EUR | 222.3M EUR | 39.0M EUR | 4.3M EUR |
| Operating income | 222.3M EUR | -130.9M EUR | -278.8M EUR | -455.5M EUR | -561.8M EUR | -451.8M EUR |
| Net income | 890.4M EUR | -219.0M EUR | -378.1M EUR | -481.4M EUR | -583.2M EUR | -383.6M EUR |
| Operating cash flow | 533.9M EUR | 51.8M EUR | -306.2M EUR | -467.4M EUR | -495.7M EUR | -417.6M EUR |
| Capital expenditure | -17.0M EUR | -8.2M EUR | -1.4M EUR | -2.4M EUR | -14.5M EUR | -24.2M EUR |
| Free cash flow | 516.9M EUR | 43.6M EUR | -307.6M EUR | -469.8M EUR | -510.2M EUR | -441.9M EUR |
| Total debt | 455.4M EUR | 871.4M EUR | 856.6M EUR | 743.1M EUR | 617.6M EUR | 209.9M EUR |
| Cash | 980.7M EUR | 615.8M EUR | 559.5M EUR | 392.2M EUR | 444.8M EUR | 446.3M EUR |
Revenue growth a year
- 1-year
- 90.2%
- 3-year
- 138.2%
- 4-year
- 207.1%
Compound growth between fiscal years.
Peers
Similar companies
- BeOne Medicines AGHKG:6160MonkScore range: 90–100
- SK Biopharmaceuticals Co., Ltd.KRX:326030MonkScore range: 90–100
- argenx SEEBR:ARGXMonkScore range: 90–100
- Nxera Pharma Co., Ltd.TYO:4565MonkScore range: 90–100
- Innovent Biologics, Inc.HKG:1801MonkScore range: 90–100
- Camurus ABSTO:CAMXMonkScore range: 90–100
- RemeGen Co., Ltd.HKG:9995MonkScore range: 90–100
- ALK-Abelló A/SCPH:ALK-BMonkScore range: 80–89
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 16 November 2026.